Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma clinicaltrials.gov Brief Summary:
This phase II trial studies how well belinostat and SGI-110…
News
To view the video on YouTube, click here
Schwartz Hunts for Predictive Biomarkers in Soft Tissue Sarcoma Gary K. Schwartz, MD, highlights research that is being done with regard to genomic signatures in sarcoma, challenges faced with immunotherapy, and where the field is headed. Gary K….
Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency Abstract One of the crucial challenges in the clinical management of cancer is resistance to chemotherapeutics. Multidrug resistance (MDR) has been intensively studied,…
Results of a Prospective Phase 2 Study of Pazopanib in Patients With Surgically Unresectable or Metastatic Chondrosarcoma
Warren Chow, MD1; Paul Frankel, PhD2; Chris Ruel, PhD2; Dejka M. Araujo, MD3; Mohammed Milhem, MBBS4; Scott Okuno, MD5; Lee…
A new article Treating Chondrosarcoma with Urgency and Compassion has just been posted on the Chondrosarcoma Web Site (www.csfshayna.org). You can find the article on the Commentaries page…
Please check out our Web Site www.csfshayna.org to get acquainted with our board of directors and staff for the Chondrosarcoma Foundation.
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas MICHAEL J. NATHENSON, ANTHONY P. CONLEY, b EDWARD SAUSVILLE, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA;…